Moran Wealth Management LLC Takes $7.94 Million Position in IQVIA Holdings Inc. $IQV

Moran Wealth Management LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 41,798 shares of the medical research company’s stock, valued at approximately $7,939,000.

Other large investors have also added to or reduced their stakes in the company. Asset Dedication LLC boosted its stake in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the last quarter. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $39,000. J.Safra Asset Management Corp raised its holdings in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the period. Rothschild Investment LLC lifted its stake in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC grew its holdings in IQVIA by 185.3% during the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 189 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $243.18 on Friday. The firm has a 50 day moving average of $223.85 and a 200-day moving average of $199.58. The firm has a market capitalization of $41.41 billion, a P/E ratio of 33.36, a price-to-earnings-growth ratio of 2.49 and a beta of 1.36. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $246.71. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the firm posted $2.84 EPS. IQVIA’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of recent research reports. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and upped their price objective for the company from $206.00 to $215.00 in a report on Monday, November 3rd. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Finally, Morgan Stanley raised their price objective on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $246.63.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.